Orthocell Ltd (ASX:OCC)’s Paul Anderson speaks with Proactive’s Andrew Scott about the outstanding results from the final data readout of all patients in its Remplir™ nerve regeneration trial at 24 months post treatment. Results show that nerve repair with Remplir™ consistently restores arm and hand function and that functional gains continued for one to two years after treatment. Nerve repair was shown to occur after serious injuries including to the spinal cord, brachial plexus and other peripheral arm/hand nerves. The Orthocell managing director also discusses the discussions the company is having with the FDA on the appropriate approval pathway that could put its technology in the hands of surgeons worldwide.
Orthocell delivers outstanding results in Remplir™ nerve regeneration trial
